Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
68,578,543
-
Total 13F shares
-
39,699,603
-
Share change
-
+3,734,870
-
Total reported value
-
$2,112,018,735
-
Put/Call ratio
-
19%
-
Price per share
-
$53.20
-
Number of holders
-
117
-
Value change
-
+$205,833,024
-
Number of buys
-
88
-
Number of sells
-
28
Institutional Holders of Zentalis Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (ZNTL) as of Q2 2021
As of 30 Jun 2021,
Zentalis Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (ZNTL) was held by
117 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
39,699,603 shares.
The largest 10 holders included
FMR LLC, Matrix Capital Management Company, LP, PRICE T ROWE ASSOCIATES INC /MD/, VANGUARD GROUP INC, TYBOURNE CAPITAL MANAGEMENT (HK) LTD, VIKING GLOBAL INVESTORS LP, BlackRock Inc., Avidity Partners Management LP, PRIMECAP MANAGEMENT CO/CA/, and STATE STREET CORP.
This page lists
117
institutional shareholders reporting positions in this security
for the Q2 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.